In the present study, we developed a novel cancer immunotherapy approach by using an oncolytic VACV co-expressing IL2 with tumor-associated antigen epitopes for the activation and amplification of cytotoxic CD8+ T and CD4+ T cells in mice. Here, CD8A is linked to cancer.